Tech Company Inital Public Offerings

Sage Therapeutics IPO

On 7/18/2014, Sage Therapeutics went public.

Transaction Overview

Company Name
Announced On
7/18/2014
Transaction Type
IPO
Amount
$90,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St.
Cambridge, MA 02142
USA
Email Address
Overview
Sage Therapeutics' (NASDAQ: SAGE) mission is to make life better for patients with nervous systems diseases by discovering, developing, and delivering important new medicines to the market.
Profile
Sage Therapeutics LinkedIn Company Profile
Social Media
Sage Therapeutics Company Twitter Account
Company News
Sage Therapeutics News
Facebook
Sage Therapeutics on Facebook
YouTube
Sage Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Jonas
  Jeffrey Jonas LinkedIn Profile  Jeffrey Jonas Twitter Account  Jeffrey Jonas News  Jeffrey Jonas on Facebook
Chief Financial Officer
Kimi Iguchi
  Kimi  Iguchi LinkedIn Profile  Kimi  Iguchi Twitter Account  Kimi  Iguchi News  Kimi  Iguchi on Facebook
Chief Medical Officer
Stephen Kanes
  Stephen Kanes LinkedIn Profile  Stephen Kanes Twitter Account  Stephen Kanes News  Stephen Kanes on Facebook
Chief Scientific Officer
Albert Robichaud
  Albert Robichaud LinkedIn Profile  Albert Robichaud Twitter Account  Albert Robichaud News  Albert Robichaud on Facebook
VP - Bus. Development
Michael Cloonan
  Michael Cloonan LinkedIn Profile  Michael Cloonan Twitter Account  Michael Cloonan News  Michael Cloonan on Facebook
VP - General Counsel
Anne Marie
  Anne Marie LinkedIn Profile  Anne Marie Twitter Account  Anne Marie News  Anne Marie on Facebook
VP - Human Resources
Erin Lanciani
  Erin Lanciani LinkedIn Profile  Erin Lanciani Twitter Account  Erin Lanciani News  Erin Lanciani on Facebook
VP - Operations
Heinrich Schlieker
  Heinrich Schlieker LinkedIn Profile  Heinrich Schlieker Twitter Account  Heinrich Schlieker News  Heinrich Schlieker on Facebook
VP - R & D
James Doherty
  James Doherty LinkedIn Profile  James Doherty Twitter Account  James Doherty News  James Doherty on Facebook
VP - Regulatory Affairs
Amy Schacterle
  Amy Schacterle LinkedIn Profile  Amy Schacterle Twitter Account  Amy Schacterle News  Amy Schacterle on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/18/2014: Alida venture capital transaction
Next: 7/18/2014: Singular venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary